Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals has reported Other Non-Current Assets for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 24.73% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 24.73% YoY), and the FY2025 full-year result was $1.2 billion, up 23.75% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.3 billion in Q1 2026, with the low at $110.7 million in Q1 2022.
• Average Other Non-Current Assets over 5 years is $734.0 million, with a median of $895.3 million recorded in 2023.
• Year-over-year, Other Non-Current Assets surged 286.18% in 2023 and increased 10.89% in 2025.
• Tracing VRTX's Other Non-Current Assets over 5 years: stood at $409.6 million in 2022, then soared by 118.58% to $895.3 million in 2023, then increased by 11.62% to $999.3 million in 2024, then gained by 23.75% to $1.2 billion in 2025, then increased by 1.6% to $1.3 billion in 2026.
• The last three Other Non-Current Assets figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison